Development of new antidepressants

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 6, 1997, Pages 40-53

  Sambunaris, Angelo ^a   Hesselink, Jan Keppel ^b   Pinder, Roger ^c   Panagides, John ^d   Stahl, Stephen M ^e  

^a Solvay Pharmaceuticals Inc   (Netherlands)

^b BAYER AG   (Germany)

^c Organon Pharmaceut Div Akzo N   (United States)

^d AKZO NOBEL CENTRAL RESEARCH   (Netherlands)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALAPROCLATE; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BAZINAPRINE; BUSPIRONE; CERICLAMINE; CLOMIPRAMINE; FEMOXETINE; FLUVOXAMINE MALEATE; IDAZOXAN; IFOXETINE; IMIPRAMINE; INOSITOL; LEVACECARNINE; LITOXETINE; MAPROTILINE; MINAPRINE; NEFAZODONE; PAROXETINE; PHENELZINE; PRASTERONE; REBOXETINE; ROLIPRAM; ROMERON; S ADENOSYLMETHIONINE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIANEPTINE; TIFLUCARBINE; TOLOXATONE; TRAZODONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VIQUALINE; ZALOSPIRONE; ZIMELDINE;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NEUROTRANSMITTER RELEASE; NORADRENALIN RELEASE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SECOND MESSENGER; SEROTONIN RELEASE;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DRUG APPROVAL; HUMANS; MIANSERIN; MONOAMINE OXIDASE INHIBITORS; NEUROTRANSMITTER UPTAKE INHIBITORS; RECEPTORS, ADRENERGIC; RECEPTORS, NEUROTRANSMITTER; SEROTONIN UPTAKE INHIBITORS;

EID: 0030792996     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (129)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, D.C.: American Psychiatric Association; 1994
2. Stahl SM. Essential Psychopharmacology. New York, NY: Cambridge University Press; 1996
3. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-418
4. Jonsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994;164:665-673
5. Hyttel J. Experimental pharmacology of selective 5-HT reuptake inhibitors: differences and similarities. Clin Neuropharmacol 1984;7(suppl 1): 866-867
6. Palvimaki EP, Laakso A, Kuoppamaki M, et al. Up-regulation of beta(1)-adrenergic receptors in rat brain after chronic citalopram and fluoxetine treatments. Psychopharmacology 1994;115:543-546
7. Banerjee SP, Kung LS, Riggi SI, et al. Development of beta-adrenoreceptor subsensitivity by antidepressants. Nature 1977;268:455-456
8. Stahl SM. Is receptor down regulation linked to the mechanism of action of antidepressant drugs? Psychopharmacol Bull 1994;30:39-43
9. Lemberger L, Fuller RW, Zerbe RL. Review: use of specific serotonin uptake inhibitors as antidepressants. Clin Neuropharmacol 1985;8:299-317
10. Nilsson BS. Adverse reactions in connection with zimeldine treatment: a review. Acta Psychiatr Scand 1983;68(suppl 308):115-119
11. Benfield P, Ward A, Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986;32:313-334
12. Whitehead AM. Fluvoxamine in the treatment of depressive illness: a series of double-blind hospital based comparative studies carried out in the UK. Br J Psychiatry 1992;46:21-23
13. Edwards JG. Selective serotonin reuptake inhibitors: a modest though welcome advance in the treatment of depression. BMJ 1992;304:1644-1645
14. Guelfi JD, White C, Magni G. A randomized double blind comparison of venlafaxine and placebo in inpatients with major depression and melancholia. Clin Neuropharmacol 1992;15(suppl 1B):323B
15. Roose SP, Glassmann AH, Attis E, et al. Comparative efficacy of the specific serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry. In press
16. Vestergaard P, Gram LF, Kragh-Srensen P, et al. Therapeutic potential of recently introduced antidepressants. Psychopharmacol Ser 1993;10:190-198
17. Gram LF. Fluoxetine. N Engl J Med 1994;331:1354-1361
18. Wernicke JF, Dunlop SR, Domseif BE, et al. Low dose fluoxetine therapy for depression. Psychopharmacol Bull 1988;24:183-188
19. Cohn JB, Wilcox C. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry 1985;46: 26-31
20. Preskorn SH, Silkey B, Beber J, et al. Antidepressant response and plasma concentrations of fluoxetine. Ann Clin Psychiatry 1991;3:147-151
21. Schweizer E, Rickels K, Amsterdam JD, et al. What constitutes an adequate antidepressant trial for fluoxetine? J Clin Psychiatry 1990;51:8-11
22. Murdoch D, McTavish DM. Sertraline, a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 1992;44:604-624
23. Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993;306: 683-687
24. Jefferson JW. Cardiovascular effects and toxicity of anxiolytics and antidepressants. J Clin Psychiatry 1989;50:368-378
25. Freeling P. Diagnosis and treatment of depression in general practice. Br J Psychiatry 1993;163(suppl 20):14-19
26. Katon W, von Korff M, Lin E, et al. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992;30:67-70
27. Milne RJ, Goa KL. Citalopram: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential of depressive illness. Drugs 1991;41:450-477
28. de Wilde J, Mertens K, Fredricson-Overo K, et al. Citalopram versus mianserin: a controlled, double-blind trial in depressed patients. Acta Psychiatr Scand 1985;72:89-96
29. Shaw DM, Thomas DR, Briscoe MH, et al. A comparison of the antidepressant action of citalopram and amitriptyline. Br J Psychiatry 1986;149: 515-517
30. Nyth AL, Gottfries CG, Lyby K, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992;86:138-145
31. Andersen G, Vestegaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994;25:104-109
32. Montgomery SA, Rasmussen IGC, Lyby K, et al. Dose response relationship in citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression. Int Clin Psychopharmacol 1992;6(suppl 5):65-70
33. Stahl SM. Targeting serotonin receptor subtypes as a strategy for the discovery of novel treatments in psychiatry. International Review of Psychiatry 1995;7:3-4
34. Preskorn SH. Should rational drug development in psychiatry target more than one mechanism of action in a single molecule? International Review Psychiatry 1995;7:17-28
35. Stahl SM, Frakes DC. Nefazodone and the serotonin receptor modulators: a new member of a unique class of antidepressant agents. International Review Psychiatry 1995;7:29-10
36. Muth EA, Haskins JT, Moyer JA, et al. Antidepressant biochemical profile of the novel bicyclic compound Wy-45.030, an ethyl cyclohexanol derivate. Biochem Pharmacol 1986;35:4493-4497
37. Clerc GE, Ruimy P, Verdeau-Pailles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:139-143
38. Mendels J, Johnston R, Mattes J, et al. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull 1993;29: 169-174
39. Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994;14:99-106
40. Troy SM, Schultz RW, Parker VD, et al. The effect of renal disease on the disposition of venlafaxine. Clin Pharmacol Ther 1994;56:14-21
41. Klamerus KJ, Maloney K, Rudolph RL, et al. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 1992;32:716-724
42. Moret C, Charveron M, Finberg JPM, et al. Biochemical profile of milnacipran, a potential fourth generation antidepressant drug. Neuropharmacology 1985;24:1211-1219
43. Macher JP. Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorder. Neuropsychobiology 1989;22:77-82
44. Macher JP, Sichel JP, Serre C, et al. Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders. Neuropsychobiology 1989;22:77-82
45. Ansseau M, Frenckell R, Mertens C, et al. Controlled comparison of two doses of milnacipran and amitriptyline in major depressed inpatients. Psychopharmacology 1989;98:163-168
46. Fontaine R, Ontiveros A, Elie R, et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994;55:234-241
47. Ferguson JM, Shrivastava R, Stahl SM. et al. Effects of double-blind treatment with nefazodone or sertraline or re-emergence of sexual dysfunction in patients with major depressive disorder [abstract]. American College of Neuropsychopharmacology 1995:242
48. Mocaer E, Rettori MC, Kamoun A. Pharmacological antidepressive effects and tianeptine-induced 5-HT uptake increase. Clin Neuropharmacol 1988; 11:S32-S42
49. Loo H, Malka R, Defrance R, et al. Tianeptine and amitriptyline: controlled double-blind trial in depressed alcoholic patients. Neuropsychobiology 1989;19:79-85
50. Guelfi JD. Efficacy of tianeptine in comparative trials versus reference antidepressants. Br J Psychiatry 1992;160(suppl 15):72-75
51. Maray C, Ganry H, Delalleau B, et al. Effect therapeutiques de la tianeptine chez des patients deprimes et anxieux avec ou sans alcoholisme associe. Presse Med 1991;20:1828-1836
52. Bourgeois M, Delalleau B, Feline A, et al. Etude de la tianeptine dans les episodes depressifs majeurs avec melancholie et signes d'endogeneite. Presse Med 1991;20:1837-1843
53. Defrance R, Marey C, Kamoun A. Antidepressant and anxiolytic activities of tianeptine: an overview of clinical trials. Clin Neuropharmacol 1988;11 (suppl 2):S74-S82
54. Olie JP, Guelfi JD, Malka R, et al. Traitements de longue duree par les antidepresseurs: la taineptine. Encephale 1988;14:379-384
55. Ferretti P, Algeri F, Benfenati F, et al. Neurochemical effect of minaprine: a novel psychotropic drug on the central cholinergic system of the rat. Psychopharmacology 1984;82:210-214
56. Montgomery SA, Baldwin DS, Priest RG, et al. Minaprine and dose response in depression: an investigation of two fixed doses of minaprine compared with imipramine. Pharmacopsychiatry 1992;24:168-174
57. Amsterdam JD, Dunner DL, Fabre LF, et al. Double-blind, placebo-controlled, fixed dose trial of minaprine in patients with major depression. Pharmacopsychiatry 1989;22:137-143
58. Wheatly D. Minaprine in depression. Br J Psychiatry 1992;161:113-115
59. Del Zompe M, Bemardi F, Burrai C, et al. A double-blind study of minaprine versus amitriptyline in major depression. Neuropsychobiology 1990;24:79-83
60. Kurtz N. Efficacy of azapirones in depression. In: Stahl SM, Gastpar M, Keppel Hesselink JM, et al, eds. Serotonin 1A Receptors in Depression and Anxiety. New York, NY: Raven Press; 1992
61. Keppel Hesselink JM. Promising anxiolytics? a new class of drugs: the azapirones. In: Stahl SM, Gastpar M, Keppel Hesselink JM, et al, eds. Serotonin 1A Receptors in Depression and Anxiety. New York, NY: Raven Press; 1992
62. Kurtz NM, Keppel Hesselink JM, Beneke M, et al. Preliminary studies of 5-HT-1A agonists in depression. Clin Neuropharmacol 1990; 13(suppl 2): 95-96
63. Robinson DS, Alms DR, Shrotriya RC, et al. Serotonergic anxiolytics and treatment of depression. Psychopathology 1989;22(suppl 1):27-36
64. Stahl SM, Gastpar M, Keppel Hesselink JM, et al. Serotonin 1A Receptors in Depression and Anxiety. New York, NY: Raven Press; 1992
65. Welner SA, de Montigny C, des Jardins P, et al. Autoradiagraphic quantification of serotonin-1A receptors in rat brain following antidepressant drug therapy. Synapse 1989;1:247-252
66. Heller AH, Beneke M, Spencer D, et al. Ipsapirone, evidence for efficacy in depression. Psychopharmacol Bull 1990;26:58-61
67. Robinson DS, Rickels K, Feighner I, et al. Clinical effects of the 5-HT-1A agonists in depression. J Clin Psychopharmacol 1990;10(suppl):67S-76S
68. Jenkins SW, Robinson DS, Fabre LF, et al. Gepirone in the treatment of major depression. J Clin Psychopharmacol 1990;10(suppl):77S-85S
69. Rausch JL, Ruegg R, Moeller FG. Gepirone as a 5-HT-1A agonist in the treatment of depression. Psychopharmacol Bull 1990;26:169-171
70. Rickels K, Amsterdam J, Clary C, et al. Buspirone in depressed outpatients: a controlled trial. Psychopharmacol Bull 1990;26:163-167
71. Ansseau M, Pitchot W, Gonzales Moreno A, et al. Pilot study of flesinoxan, a 5-HT1A agonist, in major depression: effects on sleep REM latency and body temperature. Human Psychopharmacology 1993;8:279-283
72. Schipper J, Tulp M, Berkelmans B, et al. Preclinical pharmacology of flesinoxan: a potential anxiolytic and antidepressant drug. Human Psychopharmacology 1991;6:S53-S61
73. Brusov OS, Beliaeve BS, Katasonov AB, et al. Does platelet serotonin receptor supersensitivity accompany endogenous depression? Biol Psychiatry 1989;25:375-387
74. Arora RC, Meler HY. Increased serotonin 2 receptor binding as measured by 3H-LSD in blood platelets of depressed patients. Life Sci 1989;44: 725-734
75. Janssen P. Does ritanserin, a potent serotonin S2 antagonist, restore energetic function during the night? J R Soc Med 1987;80:409-413
76. Staner L, Kempenaers C, Simonet MP, et al. 5-HT2 receptor antagonism and slow-wave sleep in major depression. Acta Psychiatr Scand 1992;86:133-137
77. Nappi G, Sandrini G, Granella F, et al. A new 5-HT2 antagonist (ritanserin) in the treatment of chronic headache with depression: a double-blind study vs amitriptyline. Headache 1990;30:439-444
78. Bersani S, Pozzi F, Marini S, et al. 5-HT-2 receptor antagonism in dysthymic disorder: a double blind placebo-controlled study with ritanserin. Acta Psychiatr Scand 1991;83:244-248
79. Janssen PA. Addiction and the potential for therapeutic drug development. EXS 1994;71:361-370
80. Naranjo CA, Bremmer KE. Serotonin-altering medication and desire, consumption and effects of alcohol-treatment implications. EXS 1994;71: 209-219
81. Crane GE. Iproniazid (Marsilid) phosphate, a therapeutic agent for mental disorders and debilitating disease. Psychiatry Research Reports 1957;8: 142-152
82. Cesura AM, Pletcher A. The new generation of monoamine oxidase inhibitors. Prog Drug Res 1992;38:171-197
83. Bass C, Kerwin R. Rediscovering monoamine oxidase inhibitors: benefits underestimated, side effects exaggerated. BMJ 1989;298:345-346
84. Priest RG. Editor's preface: antidepressants of the future. Br J Psychiatry 1989;155(suppl 6):7-8
85. Angst J, Freeman HL, Montgomery SA, et al, eds. RIMA: a new concept in the treatment of depression. Psychopharmacology 1992;106(suppl):10-15
86. Youdim MBH, De Prada M, Amrein R. The cheese effect and new reversible MAO-A inhibitors. J Neural Transm 1988:(supp 26)
87. Callingham BA. Drug interactions with reversible monoamine oxidase-A inhibitors. Clin Neuropharmacol 1993;16(suppl 2):S42-S50
88. Moller HJ, Volz HP. Brofaromine in major depressed patients: a controlled clinical trial versus imipramine and open follow up of up to one year. J Affect Disord 1992;26:163-172
89. Volz HP, Heimann H, Bellaire G, et al. Brofaromine in nonendogenous depressed inpaticnts. Pharmacopsychiatry 1994;27:152-158
90. Nolen WA, Haffmans PM, Bouvry PF, et al. Monoamine oxidase inhibitors in resistant major depression: a double blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. J Affect Disord 1993;28:189-197
91. Freeman H. Moclobemide. Lancet 1993;342:1528-1531
92. Fitton A, Faulds D, Goa KL. Moclobemide: a review of its pharmacological properties and therapeutic use in depressed illness. Drugs 1992;43: 561-596
93. Williams R, Edwards RA, Newburn GM, et al. A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders. Int Clin Psychopharmacol 1993;7:155-158
94. Bougerol T, Uchida C, Gachoud JP, et al. Efficacy and tolerability of moclobemide compared to fluvoxamine in depressed disorder. Psychopharmacology 1992;106:S102-S108
95. Versiani M, Oggero U, Alterwain P, et al. A double blind comparative trial of moclobemide versus imipramine and placebo in major depressive episode. Br J Psychiatry 1989;155(suppl 6):72-77
96. Guelfi JD, Payan C, Fermanian J, et al. Moclobemide versus clomipramine in endogenous depression. Br J Psychiatry 1992;160:519-524
97. Liebowitz MR, Schneider F, Gitow A, et al. Reversible monoamine oxidase-A inhibitors in social phobia. Clin Neuropharmacol 1993;16(suppl 2): S83-S88
98. Bakish D, Saxena BM, Bowen R, et al. Reversible monoamine oxidase-A inhibitors in panic disorder. Clin Neuropharmacol 1993;16(suppl 2): S77-S82
99. van Vliet IM, Westenberg HGM, den Boer JA. MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. Psychopharmacology 1993;112:483-489
100. de Boer T, Maura G, Raiteri M, et al. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, ORG 3770 and its enantiomers. Neuropharmacology 1988;27:399-408
101. de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 1995;10:19-24
102. Haddjeri N, Blier P, de Montigny C. Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int Clin Psychopharmacol 1995;10:11-18
103. Claghorn JL, Lesem MD. A double-blind placebo-controlled study of Org 3770 (mirtazapine) in depressed outpatients. J Affect Disord 1995;34: 165-171
104. Ruigt GSF, Kemp B, Groenhout CM, et al. Effect of the antidepressant Org 3770 on human sleep. Eur J Clin Pharmacol 1990;38:551-554
105. Sorenson M, Jorgenson J, Viby-Mogenson J, et al. A double-blind group comparative study using the new antidepressant Org 3770, placebo, and diazepam in patients with expected insomnia and anxiety before elective gynaecological surgery. Acta Psychiatr Scand 1985;71:339-346
106. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995;10:37-45
107. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995;56:519-525
108. Vartianinen H, Leinonen E. Double-blind study of mirtazapine and placebo in hospitalized patients with major depression. Eur Neuropsychopharmacol 1994;4:145-150
109. Van Moffaert M, de Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995;10:3-9
110. Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. International Clinical Research 1995;10:25-36
111. Cutler NR, Sramek JJ, Kashkin K, et al. Efficacy trial of A 75200 in patients with major depressive disorder. Biol Psychiatry 1994;35:679
112. Grebb JA, Jasinsky O, Thys R, et al. A pilot efficacy and safety study of A-75200 in patients with major depressive disorder. Neuropsychopharmacology 1994;10:161S
113. Wachtel H. Defective second-messenger function in the etiology of endogenous depression: novel therapeutic approaches. In: Briley M, Fillion G, eds. New Concepts in Depression. New York, NY: Macmillan; 1988: 277-293
114. Wachtel H. Dysbalance of neuronal second-messenger function in the etiology of affective disorders: a pathophysiological concept hypothesizing defects beyond first messenger receptors. J Neural Transm 1989;75: 21-29
115. Wachtel H. The second-messenger dysbalance hypothesis of affective disorders. Pharmacopsychiatry 1990;23:27-32
116. Kehr W, Debus G, Neumeister R. Effects of rolipram, a novel antidepressant on monoamine metabolism in rat brain. J Neural Transm 1985;63: 1-12
117. Wachtel H. Potential antidepressant activity of rolipram and other selective cAMP phosphodiesterase inhibitors. Neuropharmacology 1983;22: 267-272
118. Bertelino A, Crippa D, Di Dio S, et al. Rolipram versus imipramine with major, minor, or atypical depressive disorder: a double-blind double-dummy study aimed at testing a novel therapeutic approach. Int Clin Psychopharmacol 1988;3:245-253
119. Hebenstreit GF, Fellerer K, Fichte K, et al. Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine. Pharmacopsychiatry 1989;22:156-160
120. Behnke K, Mejer-Nielsen B, Korner A, et al. Rolipram versus nortriptyline in gerontopsychiatric inpatients with major depression. Nordic Journal of Psychiatry 1992;46:407-411
121. Fleishacker WW, Hinterhuber H, Bauer H, et al. A multicenter double-blind study of three different doses of the cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology 1992;26:59-64
122. Collins J, Abou Saleh MT. Rolipram: a new concept for the treatment of tricyclic resistant depression. Journal of Drug Development 1992;5: 65-70
123. Scott AIF, Perini AF, Shering PA, et al. Inpatient major depression: is rolipram as effective as amitriptyline? Eur J Clin Pharmacol 1991;40: 127-129
124. Onofrj M, Bodis-Wollner I, Pola P, et al. Central cholinergic effects of levo-acetyl-camitine. Experimental Clinical Research 1983;9:161
125. Bella R, Biondi R, Raffaele R, et al. Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. Int J Clin Pharmacol Res 1990;10:355-360
126. Agnioli A, Andreoli A, Casacchia M, et al. Effect of S-adenosyl-L-methionine upon depressive symptoms. Psychiatry Research 1976;13:43-54
127. Kagan BL, Sultzer DL, Rosenlicht N, et al. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 1990;147:591-595
128. Bell KM, Plon L, Bunney WE, et al. S-adenosylmethionine treatment in depression: a controlled trial. Am J Psychiatry 1988;145:1110-1114
129. Montgomery SA. Venlafaxine: a new dimension in antidepressant pharmacotherapy. J Clin Psychiatry 1993;54:3